Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years

INTRODUCTION: Solanezumab is an anti-amyloid monoclonal antibody in clinical testing for treatment of Alzheimer's disease (AD). Its mechanism suggests the possibility of slowing the progression of AD. METHODS: A possible disease-modifying effect of solanezumab was assessed using a new statistic...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Alzheimers Dement (N Y)
Glavni autori: Liu-Seifert, Hong, Siemers, Eric, Holdridge, Karen C., Andersen, Scott W., Lipkovich, Ilya, Carlson, Christopher, Sethuraman, Gopalan, Hoog, Sharon, Hayduk, Roza, Doody, Rachelle, Aisen, Paul
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2015
Teme:
Featured Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5975050/
https://ncbi.nlm.nih.gov/pubmed/29854931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2015.06.006
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items